The Neurodegeneration Medicines Acceleration Program (Neuro-MAP) led by MRC Technology is a non-profit organization that brings together promising drug projects for brain diseases like Parkinson's and Alzheimer's that have stalled due to lack of support with funding organizations. Their goal is to revive these projects by helping scientists continue their research and develop potentially effective therapies. Currently, there are more than 50 million people suffering with neurodegenerative conditions in the world, and this number is expected to increase dramatically over the next two decades. Because of this reality, Neuro-MAP believes that research should be aggressively advanced so that beneficial drugs that can treat brain diseases that are not currently being actively developed. The Neuro-MAP partners, which includes the Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society (UK), ALS Association, Michael J. Fox Foundation for Parkinson's Research, Motor Neurone Disease Association, MRC Technology, Northern Health Science Alliance, and Parkinson's UK, are seeking to do their part to match funding with promising research.